AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.
"We look forward to sharing these preclinical data on our lead product candidate tivozanib and our deep pipeline of monoclonal antibodies with our peers in the oncology research community," stated William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO. "At AVEO we are utilizing elements of our proprietary Human Response Platform™ in an effort to maximize clinical outcomes across our clinical-stage programs and identify rational drug combinations with tivozanib, as well as advance our earlier stage antibody discovery programs."
Antibody discovery could explain mysteries about COVID-19 and long COVID